fbpx
close read more

In order to optimize the success of its Research and Development projects, Servier has decided to focus its efforts in four therapeutic areas with considerable needs—oncology, immuno-inflammation, neuroscience and cardiometabolism.


ONCOLOGY

Solid tumors

COMPOUND / MOA
PROJECT
THERAPEUTIC AREA
TERRITORY
PHASE
PARTNER
FTD/TPI combo bevacizumab
S95005
Solid tumors (new indication)
Worldwide ex-US/CAN, MEX & Asia
PCD
1
2
3
FTD/TPI combo futuximab / modotuximab
S95026
Solid tumors (new indication)
Worldwide ex-US/CAN, MEX & Asia
PCD
1
2
3
Vorasidenib
S95032
Low grade Glioma with IDH 1/2 mutation
Worldwide
PCD
1
2
3
Anti-MET
S95027
Non small Cell Lung Cancer
Worldwide
PCD
1
2
3
Vorasidenib combo
S95032
Enhancing Grade 2-3 glioma with IDH1/2 mutation
Worldwide
PCD
1/2
3
Ivosidenib combo
S95031
Solid tumors (new indication)
Worldwide
PCD
1/2
3
Anti-TIM3, anti-PD1, combo irinotecan
S95018
2nd line Biliary Tract Cancer and Esophageal squamous cell carcinoma
Worldwide
PCD
1/2
3
Anti-CD73
S95024
Solid Tumors
Worldwide
PCD
1/2
3
Anti-PD-L1/4-1BB
S95012
Solid Tumors
Worldwide ex-US
PCD
1/2
3
NKG2A
S95029
Solid Tumors
Worldwide
PCD
1/2
3
MAT2A inhibitor (+/- taxane-based chemotherapy)
S95033
1st & 2nd line Metastatic Pancreatic Ductal Adenocarcinoma and Esophagal squamous cell carcinoma with MTAP-deletion
Worldwide
PCD
1/2
3
Anti-LAG3
S95017
Solid Tumors
Worldwide
PCD
1/2
3
MAT2A inhibitor
S95035
Solid Tumors
Worldwide
PCD
1
2
3

Hematological malignancies

COMPOUND / MOA
PROJECT
THERAPEUTIC AREA
TERRITORY
PHASE
PARTNER
Ivosidenib combo azacitidine
S95031
Hematological malignancies (new indication)
Worldwide
PCD
1
2
3
Licensed in China
Ivosidenib combo 7+3 (chemo)
S95031
Hematological malignancies (new indication)
Worldwide
PCD
1
2
3
Licensed in China
UCART 19
S68587/S95023
Hematological malignancies
Worldwide ex-US
PCD
1
2
3
Calaspargase pegol
S95015
Hematological malignancies (new indication)
Worldwide
PCD
1
2
3
Pegaspargase
S95014
Hematological malignancies (new indication)
Worldwide
PCD
1
2
3
Ivosidenib
S95031
Hematological malignancies (new indication)
Worldwide
PCD
1/2
3
Licensed in China
BCL-2 inhibitor
S65487
Acute Myeloid Leukemia
Worldwide ex-US/CAN, JAP, some EU countries
PCD
1/2
3
Mcl1 inhibitor
S64315
Hematological malignancies
Worldwide ex-US/CAN, JAP, some EU countries
PCD
1/2
3
Mcl1 inhibitor
S216096
Hematological malignancies
Worldwide ex-US/CAN, JAP, some EU countries
PCD
1
2
3

CARDIOMETABOLISM

Metabolism

COMPOUND / MOA
PROJECT
THERAPEUTIC AREA
TERRITORY
PHASE
PARTNER
NRF2
S227879
Non alcoholic steatohepatitis
Worldwide
PCD
1
2
3

NEUROSCIENCE

COMPOUND / MOA
PROJECT
THERAPEUTIC AREA
TERRITORY
PHASE
PARTNER
Agomelatine
S20098
Psychiatry (new indication)
Worldwide
PCD
1
2
3
LRRK2
S221237
Parkinson’s Disease
Worldwide
PCD
1
2
3

IMMUNO-INFLAMMATION

COMPOUND / MOA
PROJECT
THERAPEUTIC AREA
TERRITORY
PHASE
PARTNER
Anti-IL7R
S95011
Sjögren syndrome
Worldwide
PCD
1
2
3
Anti-IL7R
S95011
Ulcerative colitis
Worldwide
PCD
1
2
3

PCD= Preclinical development phase, 1 = Phase 1, 2 = Phase 2, 3 = Phase 3
FTD/TPI: trifluridine/ tipiracil; EGFR: epidermal growth factor receptor;
MTAP: Methylthioadenosine Phosphorylase;
IDH: Isocitrate dehydrogenase
AYA: Adolescents and Young Adults;
MOA: Mode of Action